EGFR and non-small cell lung carcinoma: ATLANTIC is the first prospective study to evaluate the efficacy of durvalumab as later treatment for advanced NSCLC,57 which was excluded because of the single‐arm study, as was the study by Jiang et al. on Toripalimab combined with chemotherapy in advanced NSCLC patients with EGFR mutation who previously treated with EGFR‐TKI.58